Pancreatic Cancer: Global Clinical Trial Landscape (2024)

Pancreatic cancer remains one of the deadliest cancers, ranking sixth in cancer-related deaths worldwide. With over 500,000 new cases reported in 2022, it poses a significant global health burden, particularly in Asia, Europe, and North America. The disease predominantly affects older adults, with higher rates in men than women, and carries a poor prognosis, with a five-year survival rate of just 2%-10%.

Leading guidelines from the NCCN, ESMO, and Japan Pancreas Society for 2024 recommend FOLFIRINOX and gemcitabine-based therapies tailored to cancer stage, diagnosis, and genetic profile. Since 2019, over 2,000 pancreatic cancer trials have been initiated, with North America, Asia-Pacific, and Europe leading research efforts. Companies like Astellas, Bristol Myers Squibb, and Sun Pharma are advancing innovative treatments through clinical trials, including antibody and stroma-modifying therapies.

The outlook for pancreatic cancer treatment is improving, with progress in chemotherapy, RAS-targeted therapies, and personalized medicine. Novotech, a global CRO, has supported over 5,000 clinical projects and is recognized for its leadership in oncology trials.

Explore the latest advancements in pancreatic cancer research with this comprehensive disease report, covering new treatments, clinical trials, and future innovations in care.